Chronic Obstructive Pulmonary Disease with CC DRG Reimbursement

DRG 191 pertains to inpatient admissions for chronic obstructive pulmonary disease with a Complication or Comorbidity; it encompasses COPD exacerbations or related respiratory illness accompanied by additional clinical conditions that increase complexity. Assignment to this Diagnosis-Related Group influences Medicare inpatient reimbursement because the Complication or Comorbidity status raises payment relative to less complex COPD cases, aligning payment with expected resource use.

DRG 191 Overview

DRG 191 covers inpatient admissions for patients treated for chronic obstructive pulmonary disease with a Complication or Comorbidity. It captures hospital resource use when COPD exacerbations or related respiratory conditions are present alongside additional clinical findings that increase care complexity. This Diagnosis-Related Group matters for Medicare payment because the presence of a Complication or Comorbidity adjusts reimbursement relative to cases without complicating conditions, reflecting higher expected resource needs. Accurate documentation and coding of the comorbid conditions determine assignment to this Diagnosis-Related Group and its associated payment weight.

Acute exacerbation intervention trials: randomized studies testing in-hospital strategies to shorten length of stay and reduce immediate complications among patients admitted with COPD exacerbations and a CC (such as respiratory failure, pneumonia, or heart failure). These trials often compare intensified medical management bundles (including oxygen strategies, noninvasive ventilation protocols, and standardized antibiotic/steroid approaches) or early integrated respiratory therapy versus usual care; the population is hospitalized adults with moderate-to-severe COPD exacerbations and at least one complicating comorbidity. Results are directly relevant to providers managing acute inpatient care and to payers because demonstrated reductions in ventilation needs, ICU transfers, or LOS can lower inpatient costs and readmission risk for this high-cost DRG.
Comparative effectiveness and comorbidity-targeted studies: pragmatic trials or observational comparative effectiveness research that evaluate different long-term COPD management strategies in patients with common CCs (for example, COPD with concomitant heart failure, diabetes, or chronic kidney disease) to determine which outpatient care pathways, medication regimens, or integrated care models best prevent readmissions. These studies enroll medically complex patients recently discharged after a COPD admission and compare coordinated care interventions (pulmonary rehabilitation referrals, multidisciplinary clinic follow-up, medication optimization algorithms) against standard post-discharge follow-up to measure 30- and 90-day readmissions, medication adherence, and health service utilization. Findings inform clinicians and payers about which targeted management approaches for comorbid populations most effectively reduce rehospitalization and downstream costs associated with DRG 191.
Post-discharge outcomes and implementation research: cohort studies and implementation trials that assess transitional care programs, home-based monitoring, and telehealth interventions for COPD patients with CC to reduce readmissions and improve functional outcomes after hospital discharge. These studies focus on older, frail patients with prior hospitalizations and significant comorbid conditions, measuring real-world outcomes such as time to first readmission, emergency visits, patient-centered measures (dyspnea scores, quality of life), and cost-effectiveness of care pathways. Results help health systems and payers prioritize which discharge planning and community-based services yield the best return on investment for patients in this DRG and guide resource allocation for post-acute care services.

Acute exacerbation intervention trials: randomized studies testing in-hospital strategies to shorten length of stay and reduce immediate complications among patients admitted with COPD exacerbations and a CC (such as respiratory failure, pneumonia, or heart failure). These trials often compare intensified medical management bundles (including oxygen strategies, noninvasive ventilation protocols, and standardized antibiotic/steroid approaches) or early integrated respiratory therapy versus usual care; the population is hospitalized adults with moderate-to-severe COPD exacerbations and at least one complicating comorbidity. Results are directly relevant to providers managing acute inpatient care and to payers because demonstrated reductions in ventilation needs, ICU transfers, or LOS can lower inpatient costs and readmission risk for this high-cost DRG.
Comparative effectiveness and comorbidity-targeted studies: pragmatic trials or observational comparative effectiveness research that evaluate different long-term COPD management strategies in patients with common CCs (for example, COPD with concomitant heart failure, diabetes, or chronic kidney disease) to determine which outpatient care pathways, medication regimens, or integrated care models best prevent readmissions. These studies enroll medically complex patients recently discharged after a COPD admission and compare coordinated care interventions (pulmonary rehabilitation referrals, multidisciplinary clinic follow-up, medication optimization algorithms) against standard post-discharge follow-up to measure 30- and 90-day readmissions, medication adherence, and health service utilization. Findings inform clinicians and payers about which targeted management approaches for comorbid populations most effectively reduce rehospitalization and downstream costs associated with DRG 191.
Post-discharge outcomes and implementation research: cohort studies and implementation trials that assess transitional care programs, home-based monitoring, and telehealth interventions for COPD patients with CC to reduce readmissions and improve functional outcomes after hospital discharge. These studies focus on older, frail patients with prior hospitalizations and significant comorbid conditions, measuring real-world outcomes such as time to first readmission, emergency visits, patient-centered measures (dyspnea scores, quality of life), and cost-effectiveness of care pathways. Results help health systems and payers prioritize which discharge planning and community-based services yield the best return on investment for patients in this DRG and guide resource allocation for post-acute care services.

OpenPayer

Summary & Overview

Chronic Obstructive Pulmonary Disease with CC: Inpatient Reimbursement Overview

DRG 191 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes